Adherence to Adalimumab in Patients with Moderate to Severe Psoriasis

West, Cameron; Narahari, Swetha; O’Neill, Jenna L.; Davis, Scott; Huynh, Monica; Clark, Adele; Boles, Ann; Feldman, Steven R.

doi:10.5070/d3195018182

Cited by 20 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By this metric, only 49%, 41%, and 29% of patients prescribed infliximab, adalimumab, and etanercept, respectively, were adherent [11]. In a one-year open-label trial, the use of extended nurse education was evaluated for its effect on adherence to adalimumab in psoriasis patients [12]. There was great variability in the number of doses taken and the days between doses in both patients who received additional nurse education as well as those who received standard physician education materials alone [13].…”

Section: Adherence To Biologics Is Poormentioning

confidence: 99%

Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management

et al. 2021

Self Cite

View full text Add to dashboard Cite

The rates of refractory pediatric psoriasis and atopic dermatitis (AD) have steadily risen over the last few decades, demanding newer and more effective therapies. This review aims to explore the reasons for resistant disease, as well as its management; this includes the indications for, efficacy of, and safety of current therapies for refractory pediatric dermatologic disease. A PubMed search for key phrases was performed. Poor medication adherence is the most common cause of resistant disease and may be managed with techniques such as simplified treatment regimens, more follow-ups and educational workshops, as well as framing and tailoring. Once problems with adherence are ruled out, escalating treatment to stronger biologic therapy may be indicated. Development of anti-drug antibodies (ADAs) can cause patients’ disease to be refractory in the presence of potent biologics, which may be addressed with regular medication use or concomitant methotrexate. If patients with AD fail to respond to biologic therapy, a biopsy to rule out mycosis fungoides, or patch testing to rule out allergic contact dermatitis, may be indicated. A limitation of this study is the absence of more techniques for the management of poor medication adherence. Managing medication adherence, escalating treatment when appropriate, and addressing possible anti-drug antibodies will help assure control and relief for patients with resistant disease.

show abstract

Section: Adherence To Biologics Is Poormentioning

confidence: 99%